– Study to Inform Phase 3 Program Design of AD109 and Advance Program for AD504 – Topline Results Expected Mid-2022 CAMBRIDGE, Mass. December 16, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address...
– Primary and secondary endpoints showed promising results for the treatment of OSA as compared to placebo – Both candidates demonstrated a favorable safety profile CAMBRIDGE, Mass. November 16, 2021 – Apnimed, a clinical-stage pharmaceutical company focused...
– Primary and key secondary endpoints showed statistically significant and clinically meaningful benefit in patients with mild to moderate OSA – AD109 was safe and well-tolerated at both doses studied – Data from a second Phase 2 study (APC-003) in patients with more...
– Primary and key secondary endpoints showed statistically significant and clinically meaningful benefit in patients with mild to severe OSA – Data showed evidence of durability-of-effect and improved quality-of-life and quality-of-sleep in open-label study extension...
CAMBRIDGE, Mass. September 27, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that Rob Rode has joined the company as Chief Commercial Officer. Mr. Rode has more...
CAMBRIDGE, Mass. August 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Canaccord...
